Arthrex Collaborates with CellRight Technologies on Distribution

By Julie A. Vetalice

CellRight Technologies entered into an agreement granting Arthrex distribution rights to its proprietary BioRinse bone portfolio in Europe, starting with the U.K. The companies entered into their first collaboration in 1Q18, addressing the U.S.

BioRinse sterilization technology is applied to CellRight's orthobiologic product families of Matrix OI®, MatrixCellect® 100 DBM putty, MatrixCellect® 100 DBM Crunch, ConCelltrate® 100, etc.

Sources: Tissue Regenix Group plc; ORTHOWORLD Inc.

Product Labels: Bone Graft Materials/DBM

Tags: M&A